What to Expect from CTAD 2020 Boston. $AVXL Blarcamesine

This Blog Is Only For Educational Purposes. Do Not Trade On This Blog Alone. Do Your Due Deligence or Consult Professional.

Let us go from the most likely to the least likely.

1. Cognitive Drug Research – Computerized Assesment System – Continuing Attension confirms the AD Phase 2a Phase 2b/3 results with decreased timing in psychomotor skils (relevant to both PD and AD, but mostly for PDD) and cognitive skill as tested by CDR-CA.
2. Background of previous point; dementias, both in PDD and AD are connected with increasing the latency in phenomenons like P300 (wave of reverseing polarity on synapses after an event like startling sound), which translates into what we laymen say about others like “he is slow”. LOL. It might be almost anecdotal but the speed of synaptic response of your nervous system is positively correlated with your IQ. So speed up and your are brighter, that what in essence measures CDR-CA, and does it in milliseconds. This is positively as much as possibly you can get to the most objective measurment of mental abilities.
3. If such outcomes are to be reported then Blarcamesine becomes the Universal Drug to Go in Dementias.
4. 78% of PDD patients develop dementia and some develop psychosis just beyond the mental ability of impairment (dementia). The impairment of mental function are called the negative symptoms, the psychosis on the other hand are called the positive since they are an “addition” to the mental condition of a person afflicted. In some sense PDD leads to dementia (negative symptoms) which then leads to psychosis (positive symptoms) not unlike schizophrenia. Is this bridge to treating schizophrenia? Does PDD Phase 2 report on these symptoms?
5. The etiology of PDD is being connected to the death of neurons in substrata nigra and resulting dopamin deficiency causing the motor skils negative symptoms. What if Blarcamesine can restor the homeostasis to those neurons and prevent neuronal death, but above all restore the levels of the neurotrasmitter in question, dopanime that is. In this way Blarcamesine becomes the drug for PDD. We only will know if the dopamine levels are direcetly measured otherwise we can reason it out of the CDR-CA results.

Published 9:52 AM on 11-6-2020 so few minutes before the presentation.